Effect of fingolimod action on the release of monocyte-derived microvesicles in multiple sclerosis patients
- PMID: 30196832
- DOI: 10.1016/j.jneuroim.2018.07.008
Effect of fingolimod action on the release of monocyte-derived microvesicles in multiple sclerosis patients
Abstract
Recently, microvesicles (MVs) were considered as important mediators of intercellular communication, especially in pathological conditions as Multiple Sclerosis (MS). In myeloid cells, MV shedding is induced by the receptor P2X7 with the involvement of acid sphingomyelinase (A-SMase) and release of the IL-1β. In this study we evaluate how Fingolimod affects MVs production by the monocytes, as well as P2X7R, IL-1β expression and A-SMase activity. Treatment decreased MVs production and IL-1β expression. This effect was associated with the inhibition of A-SMase activity in BzATP-stimulated monocytes from MS patients. These evidences suggest monocyte MVs as a possible disease and drug-efficacy biomarkers.
Keywords: Acid sphingomyelinase; Fingolimod; IL-1β; Microvesicles; Multiple sclerosis; P2X7 receptor.
Copyright © 2018 Elsevier B.V. All rights reserved.
Similar articles
-
Cytokines Stimulate the Release of Microvesicles from Myeloid Cells Independently from the P2X7 Receptor/Acid Sphingomyelinase Pathway.Front Immunol. 2018 Feb 7;9:204. doi: 10.3389/fimmu.2018.00204. eCollection 2018. Front Immunol. 2018. PMID: 29467770 Free PMC article.
-
Plasma levels of endothelial and B-cell-derived microparticles are restored by fingolimod treatment in multiple sclerosis patients.Mult Scler. 2016 Dec;22(14):1883-1887. doi: 10.1177/1352458516636959. Epub 2016 Mar 1. Mult Scler. 2016. PMID: 26931477
-
FTY720 (fingolimod) treatment tips the balance towards less immunogenic antigen-presenting cells in patients with multiple sclerosis.Mult Scler. 2015 Dec;21(14):1811-22. doi: 10.1177/1352458515574895. Epub 2015 Mar 2. Mult Scler. 2015. PMID: 25732840
-
Severe disease exacerbations in patients with multiple sclerosis after discontinuing fingolimod.Neurol Neurochir Pol. 2017 Mar-Apr;51(2):156-162. doi: 10.1016/j.pjnns.2017.01.006. Epub 2017 Feb 2. Neurol Neurochir Pol. 2017. PMID: 28209440 Review.
-
Potential neuroprotective effect of Fingolimod in multiple sclerosis and its association with clinical variables.Expert Opin Pharmacother. 2018 Mar;19(4):387-395. doi: 10.1080/14656566.2018.1434143. Epub 2018 Feb 3. Expert Opin Pharmacother. 2018. PMID: 29397790 Review.
Cited by
-
Molecular Pharmacology and Novel Potential Therapeutic Applications of Fingolimod.Front Pharmacol. 2022 Feb 16;13:807639. doi: 10.3389/fphar.2022.807639. eCollection 2022. Front Pharmacol. 2022. PMID: 35250559 Free PMC article. Review.
-
Increased NLRP3 Inflammasome Activation and Pyroptosis in Patients With Multiple Sclerosis With Fingolimod Treatment Failure.Neurol Neuroimmunol Neuroinflamm. 2023 Mar 27;10(3):e200100. doi: 10.1212/NXI.0000000000200100. Print 2023 May. Neurol Neuroimmunol Neuroinflamm. 2023. PMID: 36973075 Free PMC article.
-
Immune and central nervous system-related miRNAs expression profiling in monocytes of multiple sclerosis patients.Sci Rep. 2020 Apr 9;10(1):6125. doi: 10.1038/s41598-020-63282-3. Sci Rep. 2020. PMID: 32273558 Free PMC article.
-
Inhibition of acid or neutral sphingomyelinases differentially impacts RNA and protein cargo sorting to extracellular vesicles.iScience. 2025 Apr 15;28(5):112440. doi: 10.1016/j.isci.2025.112440. eCollection 2025 May 16. iScience. 2025. PMID: 40454089 Free PMC article.
-
Potential Roles of Extracellular Vesicles as Biomarkers and a Novel Treatment Approach in Multiple Sclerosis.Int J Mol Sci. 2021 Aug 20;22(16):9011. doi: 10.3390/ijms22169011. Int J Mol Sci. 2021. PMID: 34445717 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical